RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.

Here's Why You Should Retain Revvity Stock in Your Portfolio for Now

Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.

RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection

The S&P 500 Index ($SPX ) (SPY ) closed down by -0.02% on Thursday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.31%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.03%.  December E-mini S&P futures (ESZ26 ) fell -0.10%, and December E-mini...

Stocks Finish Mostly Lower as Bond Yields Soar

The S&P 500 Index ($SPX ) (SPY ) closed down by -0.45% on Tuesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.65%.  E-mini S&P futures (ESU26 ) fell -0.44%, and September E-mini...

Stocks Settle Lower as Crude Prices and Bond Yields Surge

RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.

Revvity to Acquire Human Cell Design to Boost Metabolic Discovery

Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.

Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Revvity, Inc. News